Methotrexate rheumatoid arthritis

In the treatment of neoplastic diseases, Methotrexate should be continued only if the potential benefit warrants the risk of severe myelosuppression. In psoriasis and rheumatoid arthritis, Methotrexate should be stopped immediately if there is a significant drop in blood counts. In patients with malignancy and preexisting hematopoietic impairment, the drug should be used with caution, if at all. Methotrexate can suppress hematopoiesis and cause anemia, aplastic anemia, leukopenia, and/or thrombocytopenia. Methotrexate should be used with extreme caution in the presence of peptic ulcer disease or ulcerative colitis. If vomiting, diarrhea, or stomatitis occur, which may result in dehydration, Methotrexate should be discontinued until recovery occurs.